Skip to main navigation Skip to search Skip to main content

Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters

  • Jason Chen
  • , Jonathan Pan
  • , Tingting Zhan
  • , Sherilyn Tuazon
  • , Neeraj Saini
  • , William O'Hara
  • , Joanne Filicko-O'Hara
  • , Thomas Klumpp
  • , Margaret Kasner
  • , Matthew Carabasi
  • , Pierluigi Porcu
  • , John L. Wagner

Research output: Contribution to journal › Article › peer-review

Abstract

Engraftment syndrome (ES) is a known complication of autologous hematopoietic stem cell transplant during neutrophil recovery. There is a limited amount of data available comparing the incidence of ES with post-transplant granulocyte colony-stimulating factor versus granulocyte macrophage colony-stimulating factor (GM-CSF), specifically in patients with multiple myeloma. Our retrospective review of 156 patients at a single center showed that GM-CSF was associated with a higher incidence of ES compared with G-CSF (32% versus 8% of patients, P < .001) and that development of ES was associated with a 32.9% (P < .001) longer hospital stay. This suggests that the choice of growth factor could possibly contribute to the development of ES and the associated costs of increased medical care.

Original languageEnglish
Pages (from-to)e293-e297
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number9
DOIs
StatePublished - Sep 2019

Keywords

  • Autologous
  • Engraftment syndrome
  • Growth factor
  • Multiple myeloma
  • Stem cell transplant

Fingerprint

Dive into the research topics of 'Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters'. Together they form a unique fingerprint.

Cite this